drugset / Trial / NCT07804186
Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a randomized, multi-center, open-label study of adjuvant darovasertib in participants with non-metastatic uveal melanoma (OptimUM-11)
Timeline
- Start
- 2026-09
- Primary completion
- 2034-03
- Completion
- 2034-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Crizotinib | Small molecule | — | Oral |
| Subject | Darovasertib | Small molecule | — | Oral |